Sunovion Pharmaceuticals will pay $100 million upfront and up to $430 million total to buy out privately held Elevation Pharmaceuticals in a deal announced Aug. 30. Central to the deal is Elevation’s Phase IIb candidate for chronic obstructive pulmonary disease (COPD), EP-101, which combines an aerosolized formulation of glycopyrrolate with a proprietary inhaler device, the eFlow Nebulizer System.
Australian regenerative medicines company Mesoblast is working with Teva to move a stem-cell treatment for congestive heart failure into Phase III.
CMS finalizes stage 2 meaningful use standards for electronic health records and delays implementation.
Multi-state settlement with Janssen over Risperdal off label marketing has a focus on reprint concerns